Why do some people accumulate Alzheimer’s plaques yet never develop dementia, while others decline? A new study points to a hidden tipping point inside the brain’s immune cells.
Scientists at VIB-KU Leuven and collaborators, writing in Nature Medicine, mapped the behaviour of microglia — the brain’s resident immune cells — across donated human brain tissue, including from cognitively healthy centenarians.
The puzzle being addressed
The disconnect between plaques and dementia is one of the central problems in the field.
Substantial numbers of people die with extensive amyloid pathology and no cognitive impairment during life. Others decline severely with comparatively modest plaque burden. Amyloid load simply does not predict symptoms well at the individual level.
That observation has undermined the simplest version of the amyloid hypothesis and helps explain why drugs that clear plaques effectively have delivered modest clinical benefit — removing plaques addresses something whose relationship to symptoms is looser than assumed.
The question this study asks is therefore the right one: not what causes plaques, but what determines whether plaques cause dementia.
The switch they found
Early in disease, microglia respond to amyloid-β plaques in a relatively contained, inflammatory way. The team identified a critical transition where microglia shift into an antigen-presenting state tied to tau pathology and neurodegeneration.
Antigen presentation is a specific and consequential function. A cell in that state displays fragments of protein on its surface for T cells to inspect, recruiting the adaptive immune system rather than acting alone.
In the brain that is a significant escalation. The organ is normally kept largely separate from adaptive immunity, and microglia adopting a presenting role means T cells are being brought into a tissue where their activity carries substantial risk of collateral damage.
Why the tau link matters
The transition being tied to tau rather than to amyloid fits a broader pattern in the field.
Tau pathology correlates with cognitive decline considerably better than amyloid does, and its spread through the brain tracks the progression of symptoms closely.
A mechanism connecting the two — where the microglial response to amyloid either does or does not tip into a state associated with tau pathology — would explain how plaques and symptoms are linked without one directly causing the other.
Whether microglia cross that threshold, or stay separated from the damaging cascade, appears to help determine whether plaques progress to dementia.
Why centenarian tissue is valuable
Including cognitively healthy centenarians is a deliberate choice with a specific logic.
Someone who reaches a hundred with intact cognition has demonstrated resilience rather than merely absence of exposure — at that age, amyloid pathology is common. They are the clearest available example of a brain that accumulated the pathology and did not succumb.
Studying resilience directly is different from studying disease. Most research compares affected brains to unaffected ones and identifies what goes wrong; this asks what protects, which points toward a different kind of intervention.
What it suggests therapeutically
Most Alzheimer’s drugs aim to clear plaques. This research suggests an alternative: keep microglia on the resilient side of the tipping point — potentially via pathways like TREM2 — to extend the brain’s natural defences.
TREM2 is a plausible lever because human genetics already implicate it: rare variants that impair its function substantially increase Alzheimer’s risk, which establishes that microglial behaviour causally affects the disease rather than merely accompanying it.
The work, “entirely based on human donor material, provides insight into one type of resilience mechanism,” said Prof. Bart De Strooper of VIB-KU Leuven.
The limits
Postmortem tissue captures single time points. A transition inferred by comparing brains at different disease stages is a reconstruction rather than an observation, and the direction of the relationship cannot be established from static samples.
What resilience research has found so far
The microglial finding joins a body of work on why some brains withstand pathology, and the other candidates provide useful context.
Cognitive reserve is the longest-established idea: people with more education, complex occupations and cognitively demanding lives tolerate more pathology before showing symptoms. The mechanism is debated — more redundant neural networks, or better compensatory strategies — and the association is consistent.
Genetic factors contribute independently. Certain variants are associated with lower risk regardless of amyloid burden, and rare protective mutations have been identified in individuals who carried strong disease-causing mutations yet remained cognitively intact far longer than expected.
Vascular health matters too. Brains with less small-vessel disease tolerate more Alzheimer’s pathology before symptoms appear, which suggests the burdens are additive.
What distinguishes a microglial mechanism is that it is potentially modifiable pharmacologically. Education and genetics are not drug targets; a cell state governed by identifiable signalling pathways is — which is why establishing that resilience runs partly through microglia would matter more practically than the observation that resilience exists.
It is early, mechanistic science, not a therapy — but it reframes where the fight against dementia might be won. Research news, not medical advice.